Molecular Partners AG (SWX:MOLN)
2.850
+0.100 (3.64%)
Oct 21, 2025, 5:31 PM CET
Molecular Partners AG Revenue
Molecular Partners AG had revenue of 681.00K CHF in the twelve months ending June 30, 2025, down -91.34% year-over-year. In the year 2024, Molecular Partners AG had annual revenue of 4.97M, down -29.38%.
Revenue (ttm)
681.00K
Revenue Growth
-91.34%
P/S Ratio
156.49
Revenue / Employee
4.45K
Employees
159
Market Cap
106.57M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 4.97M | -2.07M | -29.38% |
Dec 31, 2023 | 7.04M | -182.56M | -96.29% |
Dec 31, 2022 | 189.60M | 179.85M | 1,843.82% |
Dec 31, 2021 | 9.75M | 410.00K | 4.39% |
Dec 31, 2020 | 9.34M | -11.04M | -54.16% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Roche Holding AG | 63.49B |
Novartis AG | 43.89B |
Sandoz Group AG | 8.42B |
Alcon | 7.97B |
Lonza Group AG | 7.09B |
Galenica AG | 4.03B |
Sonova Holding AG | 3.87B |
Galderma Group AG | 3.73B |
Molecular Partners AG News
- 6 weeks ago - Looking Into Molecular Partners's Recent Short Interest - Benzinga
- 6 weeks ago - Molecular Partners (MOLN) Stock Rating Maintained by JP Morgan | MOLN Stock News - GuruFocus
- 2 months ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 months ago - EHang, Molecular Partners And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
- 2 months ago - Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025 - GlobeNewsWire
- 4 months ago - Molecular Partners and Orano Med present preclinical data on mesothelin-targeting Radio-DARPin candidate MP0726 at SNMMI 2025 - GlobeNewsWire
- 4 months ago - Molecular Partners to cut jobs, cash reach now anticipated to extend into 2028 - Seeking Alpha
- 4 months ago - Molecular Partners to cut workforce by a quarter - Reuters